Heron Therapeutics Inc. (HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post Q2 2024 Earnings of ($0.05) Per Share

Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Analysts at Capital One Financial increased their Q2 2024 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Wednesday, May 15th. Capital One Financial analyst T. Chiang now forecasts that the biotechnology company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.07). Capital One Financial has a “Overweight” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.10) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.03) EPS, FY2024 earnings at ($0.17) EPS and FY2025 earnings at $0.02 EPS. Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a report on Thursday. Read Our Latest Stock Analysis on HRTX Heron Therapeutics Price Performance Shares of NASDAQ:HRTX opened at $3.20 on Monday. The stock has a market cap of $482.08 million, a price-to-earnings ratio of -5.25 and a beta of 1.73. The company has a 50 day moving average of $2.78 and a 200-day moving average of $2.21. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.29. Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.08. The firm had revenue of $34.23 million for the quarter, compared to analyst estimates of $30.98 million. Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently bought and sold shares of HRTX. SG Americas Securities LLC acquired a new position in shares of Heron Therapeutics in the 3rd quarter valued at $31,000. Commonwealth Equity Services LLC increased its holdings in shares of Heron Therapeutics by 5.5% in the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 16,467 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Heron Therapeutics by 5.8% during the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 19,345 shares during the period. Richmond Brothers Inc. lifted its holdings in shares of Heron Therapeutics by 142.9% during the 3rd quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 60,604 shares in the last quarter. Finally, Monaco Asset Management SAM grew its position in shares of Heron Therapeutics by 72.1% in the 3rd quarter. Monaco Asset Management SAM now owns 696,908 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 291,908 shares during the period. Institutional investors own 80.01% of the company’s stock. About Heron Therapeutics (Get Free Report) Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. See Also Five stocks we like better than Heron Therapeutics Stock Dividend Cuts Happen Are You Ready? MarketBeat Week in Review – 5/13 – 5/17 What is the Dow Jones Industrial Average (DJIA)? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Warren Buffett Stocks to Buy Now Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook